Two Senior Business Development Executives Join Life Biosciences




Senior Professionals Named to Identify New Scientific Investments & Strategic Partnerships

For Innovative Company Combating Age-Related Decline


Boston, October 25 –Michael Ringel, PhD, and Sree Kant have been appointed to senior business development positions, according to an announcement today by Life Biosciences Inc. Sree Kant is the head of Business Development and Dr. Ringel is a strategic advisor of that department. Together they work with the leadership of Life Biosciences and its six Daughter companies as they pursue their independent and collaborative research into the eight pathways of age-related decline (ARD).

“We are excited by the addition of Sree and Michael to our team,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Together they support our work, helping to research, identify and develop new scientific investments and strategic partnerships. This pursuit and support of fresh thinking is foundational to the goals and structure of Life Biosciences.”

Mr. Kant comes to Life with 18 years of varied healthcare and pharmaceutical industry experience. He previously was the head of early partnering strategy for Pfizer, across different therapeutic areas/technologies and geographies with Academia, VCs/Banks, CROs, and other strategic partners. He was also a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. He has an MBA from the Indian Institute of Management, and an MPH from the Harvard School of Public Health. Mr. Kant is an invited speaker at key industry events and conferences on subjects of R&D strategy, innovative partnering models, industry-academia collaborations, early-stage technologies and investments.

Dr. Ringel has 20 years of experience focused on corporate development, partnering, and R&D innovation. He is concurrently a Senior Partner and Managing Director at The Boston Consulting Group, where he is the Global Topic Leader for Research and Product Development. He is a frequent contributor to industry journals and a popular public speaker, including having a TED talk on biopharma R&D partnering. Dr. Ringel has a BA in biology summa cum laude from Princeton University, a PhD in biology from Imperial College, and a JD cum laude from Harvard Law School.

#              #          #


Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 25,000 square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company’s Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals.

 For more information on Life Biosciences, please visit


Press Contact: